A detailed history of Chevy Chase Trust Holdings, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Chevy Chase Trust Holdings, Inc. holds 446,861 shares of VRTX stock, worth $210 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares
446,861
Previous 453,429 1.45%
Holding current value
$210 Million
Previous $213 Million 2.21%
% of portfolio
0.64%
Previous 0.68%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $3.02 Million - $3.32 Million
-6,568 Reduced 1.45%
446,861 $208 Million
Q2 2024

Jul 22, 2024

BUY
$392.81 - $485.53 $3.77 Million - $4.66 Million
9,604 Added 2.16%
453,429 $213 Million
Q1 2024

May 03, 2024

SELL
$407.69 - $446.08 $458,243 - $501,393
-1,124 Reduced 0.25%
443,825 $186 Million
Q4 2023

Jan 24, 2024

BUY
$343.0 - $410.68 $4.91 Million - $5.88 Million
14,311 Added 3.32%
444,949 $181 Million
Q3 2023

Oct 23, 2023

BUY
$338.18 - $362.46 $4.99 Million - $5.34 Million
14,744 Added 3.55%
430,638 $150 Million
Q2 2023

Jul 25, 2023

BUY
$314.42 - $351.91 $24.2 Million - $27.1 Million
77,125 Added 22.77%
415,894 $146 Million
Q1 2023

May 17, 2023

BUY
$283.23 - $323.1 $94.6 Million - $108 Million
334,172 Added 7269.35%
338,769 $107 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $59.9 Million - $68.3 Million
-211,432 Reduced 97.87%
4,597 $1.45 Billion
Q4 2022

Feb 09, 2023

BUY
$285.76 - $321.48 $17 Million - $19.1 Million
59,356 Added 37.89%
216,029 $62.4 Million
Q3 2022

Nov 04, 2022

BUY
$273.83 - $305.53 $588,460 - $656,583
2,149 Added 1.39%
156,673 $45.4 Million
Q2 2022

Aug 10, 2022

BUY
$234.96 - $292.55 $308,267 - $383,825
1,312 Added 0.86%
154,524 $43.5 Million
Q1 2022

Apr 27, 2022

BUY
$221.42 - $260.97 $102,296 - $120,568
462 Added 0.3%
153,212 $40 Million
Q4 2021

Jan 31, 2022

SELL
$177.01 - $223.45 $1.16 Million - $1.46 Million
-6,536 Reduced 4.1%
152,750 $33.5 Million
Q3 2021

Oct 20, 2021

SELL
$181.39 - $202.99 $1.03 Million - $1.15 Million
-5,666 Reduced 3.43%
159,286 $28.9 Million
Q2 2021

Jul 20, 2021

SELL
$187.49 - $221.1 $1.78 Million - $2.1 Million
-9,520 Reduced 5.46%
164,952 $33.3 Million
Q1 2021

Apr 22, 2021

SELL
$207.02 - $241.31 $2.97 Million - $3.46 Million
-14,332 Reduced 7.59%
174,472 $37.5 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $3.59 Million - $4.79 Million
-17,366 Reduced 8.42%
188,804 $44.6 Million
Q3 2020

Nov 06, 2020

SELL
$255.65 - $303.1 $3.84 Million - $4.55 Million
-15,023 Reduced 6.79%
206,170 $56.1 Million
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $1.7 Million - $2.24 Million
-7,558 Reduced 3.3%
221,193 $64.2 Million
Q1 2020

May 13, 2020

BUY
$199.77 - $247.81 $504,619 - $625,968
2,526 Added 1.12%
228,751 $54.4 Million
Q4 2019

Feb 12, 2020

SELL
$166.71 - $223.91 $248,898 - $334,297
-1,493 Reduced 0.66%
226,225 $49.5 Million
Q3 2019

Nov 20, 2019

SELL
$166.23 - $187.09 $77,130 - $86,809
-464 Reduced 0.2%
227,718 $38.6 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $201,153 - $232,632
-1,222 Reduced 0.53%
228,182 $41.8 Million
Q1 2019

May 13, 2019

BUY
$163.73 - $194.7 $405,395 - $482,077
2,476 Added 1.09%
229,404 $39.1 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $2.59 Million - $3.27 Million
-17,032 Reduced 6.98%
226,928 $37.6 Million
Q3 2018

Oct 23, 2018

SELL
$167.73 - $192.74 $744,721 - $855,765
-4,440 Reduced 1.79%
243,960 $47 Million
Q2 2018

Aug 02, 2018

BUY
$145.72 - $169.96 $23,169 - $27,023
159 Added 0.06%
248,400 $42.2 Million
Q1 2018

Apr 10, 2018

SELL
$151.6 - $177.13 $723,890 - $845,795
-4,775 Reduced 1.89%
248,241 $40.5 Million
Q4 2017

Jan 22, 2018

SELL
$137.28 - $155.55 $126,572 - $143,417
-922 Reduced 0.36%
253,016 $37.9 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $37.6 Million - $41.2 Million
253,938
253,938 $38.6 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Chevy Chase Trust Holdings, Inc. Portfolio

Follow Chevy Chase Trust Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chevy Chase Trust Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chevy Chase Trust Holdings, Inc. with notifications on news.